Document is current
Any future updates will be listed below
-
Authors
Seaton, Natasha
Wileman, Vari
Norton, Christine
Hudson, Joanna
Mondelli, Valeria
Moss-Morris, Rona
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/N013700/1)
National Institute of Health Research (NIHR203318, RP-PG-0216-20001, NIHR203318, NIHR203318, NIHR203318)
- License Information
-
More Information
Article History
Received: 1 October 2024
Accepted: 13 February 2025
First Online: 6 March 2025
Declarations
:
: The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Favourable ethical opinion was granted for the trial and the risk assessment protocol by a Research Ethics Committee (London - Surrey Research Ethics Committee/ 19/LO/0750).
: All participants provided written informed consent for participation and publication before their commencement in the study.
: CN has received speaker fees from Janssen, WebMD, Medscape, Merck Pharmaceutical; Tillotts Pharms UK. Pfizer advisory board. RMM is a beneficiary of a licence agreement signed between King’s College London and Mahana Therapeutics for a digital cognitive behavioural therapy for an irritable bowel syndrome product. RMM receives personal fees from Mahana Therapeutics for scientific advisory work and from other universities and hospital trusts for cognitive behavioural therapy training in irritable bowel syndrome. Co-authors declare no further competing interests.
